Exposure to Persistent Organic Pollutants and Severity of Endometriosis in the ComPaRe-Endometriosis Cohort

Condition(s) studied

Investigational drug(s) / intervention(s)

Blood samples: 24mL blood sample (3 dry tubes with 8mL)

Study summary

Endometriosis is a chronic inflammatory disease affecting \~10% of women of childbearing age. It is characterized by the presence of endometrial-like tissue outside the uterus, causing lesions and adhesions between the organs, and is often accompanied by intense pain and sometimes infertility. The four-stage classification based on the severity of lesions does not always reflect the severity of symptoms. Adenomyosis, a similar pathology, is often present in the same patients, although it is now considered distinct from endometriosis. Diagnosis usually takes a long time, with an average delay of 7 years. The cause of the disease remains unknown, but hormonal, genetic and environmental factors, such as exposure to endocrine disruptors, are suspected. Persistent organic pollutants (POPs), such as dioxins and PCBs, may influence the risk and severity of the disease. Although experimental studies suggest a link between these substances and the progression of endometriosis, epidemiological research on the subject is still limited.

The central hypothesis of the POPENDO project is that higher concentrations of persistent organic pollutants (POPs) are associated with increased severity of endometriosis. The aim of the study is to explore the associations between serum levels of four families of POPs (PCBs, organochlorine pesticides, PFAS and BFR) and endometriosis.

Eligibility

Primary outcome measure(s)

• Assessment of the severity of endometriosis, defined by the type of disease. — During 3 last years of analysis
  Analysis of several online questionnaires on endometriosis by participants
• Evaluation of serum levels of polychlorinated biphenyls (PCBs) — 5 months after inclusion start until analysis of the last participant' blood sample
  Chemical analysis of participants' blood samples by the LABERCA laboratory
• Evaluation of serum levels of per- and polyfluoroalkylates (PFAS) — 5 months after inclusion start until analysis of the last participant' blood sample
  Chemical analysis of participants' blood samples by the LABERCA laboratory
• Evaluation of serum levels of Brominated flame retardants polluent (BFRs) — 5 months after inclusion start until analysis of the last participant' blood sample
  Chemical analysis of participants' blood samples by the LABERCA laboratory
• Evaluation of serum levels of organochlorine pesticides (POCs) — 5 months after inclusion start until analysis of the last participant' blood sample
  Chemical analysis of participants' blood samples by the LABERCA laboratory

Trial sites (1)

More Institut National de la Santé Et de la Recherche Médicale, France trials in France

Other trials for the same condition